
    
      This phase 2 study is a double-blind, placebo controlled, parallel arm study with a 4 week
      run-in and an 8-week treatment period. It will assess the safety and tolerability of
      fispemifene, and the effects of treatment on the sexual side effects seen in this patient
      population using PRO endpoints.
    
  